• Consensus Rating: Sell
  • Consensus Price Target: $6.25
  • Forecasted Upside: 846.83 %
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.66
▲ +0.09 (15.79%)

This chart shows the closing price for ATHX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athersys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHX

Analyst Price Target is $6.25
▲ +846.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Athersys in the last 3 months. The average price target is $6.25, with a high forecast of $6.25 and a low forecast of $6.25. The average price target represents a 846.83% upside from the last price of $0.66.

This chart shows the closing price for ATHX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Athersys. This rating has held steady since October 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022Bank of AmericaDowngradeBuy ➝ Underperform$25.00 ➝ $6.25High
3/16/2022Bank of AmericaLower TargetNeutral$31.25 ➝ $25.00Medium
11/19/2021Bank of AmericaDowngradeBuy ➝ Neutral$31.25High
11/10/2020Needham & Company LLCReiterated RatingBuy$125.00High
10/12/2020Dawson JamesReiterated RatingBuyLow
8/11/2020Needham & Company LLCReiterated RatingBuy$125.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$125.00High
5/8/2020Needham & Company LLCLower TargetBuy$150.00 ➝ $125.00Low
5/6/2020Dawson JamesReiterated RatingBuy$300.00Low
4/23/2020Smith Barney CitigroupInitiated CoverageOutperform$350.00Low
8/26/2019Dawson JamesInitiated CoverageBuy$275.00High
5/9/2019Maxim GroupReiterated RatingBuy$200.00High
1/23/2019Maxim GroupSet TargetBuy$200.00High
8/8/2018Maxim GroupReiterated RatingBuy$150.00High
7/31/2018Maxim GroupReiterated RatingBuy$150.00High
5/11/2018Maxim GroupSet TargetBuy$150.00Low
4/23/2018Maxim GroupInitiated CoverageBuy$150.00Medium
3/13/2018Maxim GroupReiterated RatingBuy$150.00High
2/13/2018Maxim GroupSet TargetBuy ➝ Buy$300.00 ➝ $150.00Medium
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 0 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/11/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/10/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/9/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Athersys logo
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Read More

Today's Range

Now: $0.66
Low: $0.56
High: $0.69

50 Day Range

MA: $1.40
Low: $0.51
High: $2.69

52 Week Range

Now: $0.66
Low: $0.50
High: $33.25

Volume

486,418 shs

Average Volume

684,495 shs

Market Capitalization

$7.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Athersys?

The following Wall Street analysts have issued research reports on Athersys in the last twelve months: Bank of America Co., and StockNews.com.
View the latest analyst ratings for ATHX.

What is the current price target for Athersys?

1 Wall Street analysts have set twelve-month price targets for Athersys in the last year. Their average twelve-month price target is $6.25, suggesting a possible upside of 999.6%. Bank of America Co. has the highest price target set, predicting ATHX will reach $6.25 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.25 for Athersys in the next year.
View the latest price targets for ATHX.

What is the current consensus analyst rating for Athersys?

Athersys currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe ATHX will underperform the market and that investors should sell shares of Athersys.
View the latest ratings for ATHX.

What other companies compete with Athersys?

How do I contact Athersys' investor relations team?

Athersys' physical mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company's listed phone number is (216) 431-9900 and its investor relations email address is [email protected] The official website for Athersys is www.athersys.com. Learn More about contacing Athersys investor relations.